HCM vs. INDV, HIK, GNS, SPI, ONT, CRW, CTEC, SN, BMK, and APH
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Indivior (INDV), Hikma Pharmaceuticals (HIK), Genus (GNS), Spire Healthcare Group (SPI), Oxford Nanopore Technologies (ONT), Craneware (CRW), ConvaTec Group (CTEC), Smith & Nephew (SN), Benchmark (BMK), and Alliance Pharma (APH). These companies are all part of the "medical" sector.
HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
In the previous week, Indivior had 1 more articles in the media than HUTCHMED. MarketBeat recorded 2 mentions for Indivior and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.67 beat Indivior's score of 0.18 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED has higher earnings, but lower revenue than Indivior. HUTCHMED is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
HUTCHMED has a net margin of 12.03% compared to Indivior's net margin of 0.18%. HUTCHMED's return on equity of 14.65% beat Indivior's return on equity.
HUTCHMED has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Indivior has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500.
32.3% of HUTCHMED shares are held by institutional investors. Comparatively, 92.9% of Indivior shares are held by institutional investors. 42.9% of HUTCHMED shares are held by company insiders. Comparatively, 3.2% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Indivior has a consensus target price of GBX 2,515, indicating a potential upside of 75.26%. Given Indivior's higher possible upside, analysts plainly believe Indivior is more favorable than HUTCHMED.
Indivior received 360 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 80.35% of users gave Indivior an outperform vote while only 78.40% of users gave HUTCHMED an outperform vote.
Summary
Indivior beats HUTCHMED on 9 of the 17 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
